This article describes the populations at high risk for HIV infection and reports the results of a collaborative, multifaceted educational intervention designed to reduce the documented disparities related to HIV care and prevention.
Although the CDC recommends routine HIV screening for all people age 13-64 years, numerous barriers to HIV testing in healthcare settings have been identified, including lack of access and fear of stigma and discrimination.
When comparing hormonal contraceptive methods, particularly IM depot medroxyprogesterone acetate with an IUD and a levonorgestrel implant, there was no substantial difference in HIV risk among African women.
Findings of a recently updated systematic review support the WHO recommendation that children infected with HIV should be revaccinated against measles following immune reconstitution with combination antiretroviral therapy.
Compared with Alere Determine TB LAM Ag (AlereLAM), the only commercially available tuberculosis point-of-care test, the novel Fujifilm SILVAMP TB LAM (FujiLAM) assay offers superior diagnostic sensitivity while also maintaining specificity, according to a study published in The Lancet: Infectious Diseases. The applicability of FujiLAM in various settings requires prospective assessment, but the test could be…
In patients who are immunocompromised, such as people living with HIV, the new fourth-generation QuantiFERON-TB Gold Plus assay demonstrated similar sensitivity to the third-generation interferon-gamma release assay for the diagnosis of latent tuberculosis.
Avirulins may provide a valuable chemical foundation for the development of the next generation of prophylactic medications for HIV-1 in women, according to results of a study presented at American Society of Microbiology (ASM) Microbe 2019 held from June 20-24, 2019, in San Francisco, California. Although much progress has been made in decreasing the risk…
The pediatric approval was based on data from an open label, single arm trial that evaluated the efficacy, safety, and pharmacokinetics of Biktarvy in virologically suppressed children (6 to <12 years old; n=50) and adolescents (12 to <18 years old; n=50).